Stock listing
HKEX:9887 Nanjing Leads Biolabs Co., Ltd. (維立志博) 股價
Home listing (HKEX) of Nanjing Leads Biolabs Co., Ltd.
Follow Nanjing Leads Biolabs Co., Ltd. into a list and get an email when it puts out news.
Share price · HKEX:9887
$34.10 HKD -1.12 (-3.2%)
Close on Nov 3, 2026
- Day range
- $33.68 – $35.60 HKDNov 3, 2026
- Volume
- 922,600 sharesNov 3, 2026
- Market cap
- $5.23B HKDAt the close on Nov 3, 2026 · price × 153.3M shares outstanding
- 52-week range
- $33.68 – $97.50 HKDLowest and highest trades, Nov 4, 2025 – Nov 3, 2026
- Traded on an average day
- $98.22M HKDMedian day 1.48M shares · last 3 months, Aug 3, 2026 – Nov 3, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:9887 · Home | $34.10 HKD | -1.12 (-3.2%) | 922,600 | $34.64 | $35.60 | $33.68 | $35.22 | Close on Nov 3, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 3, 2026 · HKEX:9887 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $34.10 | -1.12 | -3.2% | $34.64 | $35.60 | $33.68 | 922,600 | |
| $35.22 | -0.78 | -2.2% | $35.70 | $36.44 | $34.68 | 800,100 | |
| $36.00 | -0.98 | -2.7% | $36.40 | $37.50 | $36.00 | 387,600 | |
| $36.98 | -0.82 | -2.2% | $38.50 | $38.50 | $36.80 | 458,800 | |
| $37.80 | +0.52 | +1.4% | $38.28 | $38.84 | $37.24 | 723,000 | |
| $37.28 | +2.32 | +6.6% | $35.90 | $38.20 | $35.70 | 2,256,600 | |
| $34.96 | -0.84 | -2.3% | $36.48 | $36.50 | $34.60 | 1,116,000 | |
| $35.80 | -1.16 | -3.1% | $37.00 | $37.00 | $34.78 | 1,556,700 | |
| $36.96 | -2.96 | -7.4% | $40.28 | $40.64 | $36.46 | 1,802,700 | |
| $39.92 | -3.02 | -7.0% | $43.72 | $44.58 | $39.82 | 1,775,800 | |
| $42.94 | +1.64 | +4.0% | $42.00 | $44.80 | $41.34 | 1,408,500 | |
| $41.30 | +0.64 | +1.6% | $42.60 | $42.60 | $40.56 | 1,132,800 | |
| $40.66 | -1.28 | -3.1% | $42.00 | $42.32 | $40.10 | 1,333,400 | |
| $41.94 | -2.56 | -5.8% | $45.28 | $45.28 | $41.74 | 1,287,300 | |
| $44.50 | -1.12 | -2.5% | $45.62 | $45.62 | $43.22 | 1,227,750 | |
| $45.62 | +0.06 | +0.1% | $46.20 | $46.84 | $45.04 | 1,067,850 | |
| $45.56 | +0.40 | +0.9% | $45.18 | $46.44 | $43.62 | 1,282,100 | |
| $45.16 | -4.44 | -9.0% | $49.52 | $50.80 | $45.02 | 2,370,402 | |
| $49.60 | -1.30 | -2.6% | $50.05 | $50.10 | $47.74 | 467,400 | |
| $50.90 | +0.45 | +0.9% | $51.00 | $51.20 | $50.10 | 217,889 | |
| $50.45 | 0.00 | 0.0% | $51.95 | $51.95 | $49.06 | 220,405 | |
| $50.45 | -1.60 | -3.1% | $51.25 | $52.25 | $49.06 | 280,600 | |
| $52.05 | +1.65 | +3.3% | $50.65 | $52.35 | $50.15 | 698,100 | |
| $50.40 | +0.42 | +0.8% | $50.80 | $51.45 | $49.86 | 930,400 | |
| $49.98 | -2.32 | -4.4% | $53.40 | $53.40 | $48.90 | 2,729,300 | |
| $52.30 | -0.25 | -0.5% | $52.30 | $54.50 | $50.80 | 228,808 | |
| $52.55 | -3.65 | -6.5% | $55.85 | $55.85 | $52.40 | 1,645,703 | |
| $56.20 | +2.05 | +3.8% | $53.60 | $58.05 | $53.60 | 2,593,500 | |
| $54.15 | -3.10 | -5.4% | $57.50 | $57.50 | $53.35 | 1,992,100 | |
| $57.25 | +1.50 | +2.7% | $57.05 | $59.15 | $55.40 | 1,976,500 | |
| $55.75 | 0.00 | 0.0% | $56.15 | $57.25 | $55.50 | 1,003,100 | |
| $55.75 | +1.65 | +3.0% | $55.60 | $57.60 | $55.10 | 2,360,002 | |
| $54.10 | -3.00 | -5.3% | $56.95 | $57.50 | $52.75 | 2,922,500 | |
| $57.10 | -4.40 | -7.2% | $63.00 | $65.75 | $56.20 | 6,432,300 | |
| $61.50 | +1.30 | +2.2% | $60.15 | $61.95 | $56.80 | 2,066,700 | |
| $60.20 | -1.80 | -2.9% | $62.00 | $62.35 | $60.10 | 1,267,064 | |
| $62.00 | -1.20 | -1.9% | $63.20 | $63.30 | $61.00 | 1,112,700 | |
| $63.20 | -0.10 | -0.2% | $63.35 | $64.75 | $61.90 | 1,657,300 | |
| $63.30 | +1.10 | +1.8% | $62.50 | $64.50 | $61.75 | 1,711,000 | |
| $62.20 | -1.80 | -2.8% | $64.00 | $65.60 | $62.10 | 1,413,300 | |
| $64.00 | -3.70 | -5.5% | $69.00 | $69.00 | $63.55 | 3,869,200 | |
| $67.70 | +0.75 | +1.1% | $67.00 | $69.25 | $65.55 | 1,900,300 | |
| $66.95 | -0.65 | -1.0% | $69.00 | $69.00 | $65.25 | 2,729,800 | |
| $67.60 | -4.70 | -6.5% | $72.80 | $73.50 | $67.20 | 2,933,300 | |
| $72.30 | +0.35 | +0.5% | $73.85 | $73.85 | $69.75 | 1,444,087 | |
| $71.95 | -0.10 | -0.1% | $70.50 | $73.00 | $70.50 | 933,100 | |
| $72.05 | +0.65 | +0.9% | $72.40 | $72.90 | $70.40 | 806,800 | |
| $71.40 | -3.20 | -4.3% | $75.05 | $76.25 | $70.85 | 1,757,971 | |
| $74.60 | +5.55 | +8.0% | $69.55 | $75.40 | $67.35 | 2,492,492 | |
| $69.05 | -2.15 | -3.0% | $73.35 | $73.45 | $68.25 | 1,421,543 | |
| $71.20 | -4.90 | -6.4% | $76.00 | $76.15 | $70.35 | 2,304,503 | |
| $76.10 | +5.65 | +8.0% | $74.05 | $77.65 | $70.20 | 3,362,211 | |
| $70.45 | -2.55 | -3.5% | $74.00 | $75.05 | $69.80 | 1,181,908 | |
| $73.00 | -1.90 | -2.5% | $75.80 | $76.80 | $71.40 | 1,479,013 | |
| $74.90 | +1.60 | +2.2% | $73.60 | $78.40 | $72.10 | 2,702,917 | |
| $73.30 | +4.15 | +6.0% | $69.15 | $73.60 | $67.10 | 2,522,224 | |
| $69.15 | +2.70 | +4.1% | $67.30 | $69.65 | $65.60 | 1,699,634 | |
| $66.45 | +0.70 | +1.1% | $67.45 | $67.50 | $65.20 | 1,098,621 | |
| $65.75 | -0.65 | -1.0% | $67.00 | $67.80 | $65.20 | 1,337,835 | |
| $66.40 | +2.10 | +3.3% | $65.40 | $68.20 | $64.95 | 1,655,200 | |
| $64.30 | +1.95 | +3.1% | $62.40 | $65.25 | $62.00 | 1,903,200 | |
| $62.35 | +4.30 | +7.4% | $58.60 | $63.60 | $58.55 | 2,630,100 | |
| $58.05 | -0.40 | -0.7% | $58.35 | $59.50 | $56.65 | 1,407,940 | |
| $58.45 | +1.50 | +2.6% | $57.50 | $59.60 | $56.40 | 2,099,500 | |
| $56.95 | +3.55 | +6.6% | $54.15 | $56.95 | $52.50 | 2,822,928 |
- Ticker
- HKEX:9887
- Asset type
- Stock
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Latest deck · May 2026
Investor Presentation (May 2026)
Investor deck · 62 slides
Latest news
Voluntary announcement part B of LBL-047 phase i study completes first dosing of a patient with systemic lupus erythematosus; novel BDCA2/TACI dual-targeting design enters clinical evaluation in patients
Oct 30, 2026
Closed $36.00 (-2.7%) on Oct 30, 2026
Voluntary announcement presentation of updated clinical and translational data of LBL-024 for extrapulmonary neuroendocrine carcinoma, biliary tract cancer and colorectal cancer at 2026 esmo
Oct 26, 2026
Closed $37.28 (+6.6%) on Oct 27, 2026
Voluntary announcement oral presentation of updated clinical data of LBL-034 for relapsed/refractory multiple myeloma at 2026 ESMO
Oct 25, 2026
Closed $34.96 (-2.3%) on Oct 26, 2026
Voluntary announcement phase ii study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) as first-line treatment for gastric cancer progresses to expansion stage
Oct 20, 2026
Closed $39.92 (-7.0%) on Oct 21, 2026
Voluntary announcement abstracts of six studies published at 2026 ESMO
Oct 19, 2026
Closed $42.94 (+4.0%) on Oct 20, 2026
Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
Oct 16, 2026
Closed $41.30 (+1.6%) on Oct 16, 2026
Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
Oct 11, 2026
Closed $45.62 (+0.1%) on Oct 12, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 2, 2026
Closed $50.45 (0.0%) on Oct 5, 2026
Decks
Investor Presentation (May 2026)
Investor deck · 62 slides · May 2026
Leads Biolabs — Investor Presentation (November 2025)
Investor deck · 56 slides · November 2025
Nanjing Leads Biolabs Co., Ltd. on 6ix
- News releases
- 34 in the last 12 months · 40 in all · newest Nov 3, 2026 · oldest 2025
- Decks
- 2 decks · latest May 2026
Where Nanjing Leads Biolabs Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:9887 維立志博 · Home listing · This page | HKEX | Hong Kong | HKD |
| LS Exchange:A41ESB | LS Exchange | Germany | EUR |
| Frankfurt:0DX | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41ESB | Lang & Schwarz | Germany | EUR |
| Tradegate:0DX | Tradegate | Germany | EUR |
Log in to ask 6ix AI your own questions about Nanjing Leads Biolabs Co., Ltd.